Pazopanib in patients with primary multi-metastatic bone Ewing sarcoma
Frontiers in Oncology · 23.10.2025 · 15
DOI: 10.3389/fonc.2025.1653015 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Oncology, online erschienen am 23.10.2025. Verfasst von Anna Raciborska und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology and Surgical Oncology for Children and Youth, Institute of Mother and Child, Warsaw, Poland. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Despite the use of different treatment regimens, patients with primary multi-metastatic Ewing sarcoma disease have a dismal outcome. Lately, pazopanib has been proposed as an effective salvage regimen for soft tissue sarcoma (STS), including extraosseous Ewing sarcoma (ESS). Thus, we sought to evaluate this approach for young patients with primary multi-metastatic bone Ewing sarcoma. Materials and methods Eleven patients with primary multi-metastatic bone Ewing sarcoma (metastasis to the bone and/or bone marrow), received standard first-line treatment in parallel with pazopanib. All patients had standard tumor imaging and laboratory evaluation. All toxicities were documented.
Results
Pazopanib was administered throughout the whole treatment period (paused during the surgical procedure) and after its completion, on average 1.7 years (range 0.9 to 5.1). At the time of the beginning of pazopanib, the median age was 14.2 years (range 5.1 to 17.8 years). The primary tumor was operated on in five patients. Ten patients received concurrent radiation therapy, and 3 autologous hematopoietic stem cell transplantation. Significant toxicities have not been observed. One patient (9.1%) progressed. Two patients had relapse (18.2%), and one patient died (9.1%). Ten patients (90.9%) are alive with a median time follow-up 2.6 years (range 1.2 to 9.2 years). The estimated 2-year event-free survival and overall survival for the whole group were 68.2% and 85.7%, respectively.
Conclusions
Pazopanib was well-tolerated in young patients, even when it was administered with chemotherapy and radiation therapy together. Pazopanib turned out to be effective in patients with primary multi-metastatic Ewing sarcoma and particularly could be considered as an option for them. This regimen deserves further investigation.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Oncology and Surgical Oncology for Children and Youth, Institute of Mother and Child, Warsaw, Poland.
- Department and Clinic of Pediatric Oncology, Hematology and Bone Marrow Transplantation, Wroclaw Medical University, Wroclaw, Poland.
- Department of Pediatric Oncohematology, Rzeszow University, Rzerzow, Poland.
- Department of Pediatric Hematology and Oncology, Silesian Medical University, Zabrze, Poland.
Zitieren
APA
Raciborska, A., Bilska, K., Węcławek-Tompol, J., Sega-Pondel, D., Zelwiańska, A., Przybyszewski, B., Chaber, R., Tomaszewska, R., Antoniuk-Majchrzak, J., & Koziński, T. (2025). Pazopanib in patients with primary multi-metastatic bone Ewing sarcoma. Frontiers in Oncology, 15. https://doi.org/10.3389/fonc.2025.1653015
Vancouver
Raciborska A, Bilska K, Węcławek-Tompol J, Sega-Pondel D, Zelwiańska A, Przybyszewski B, et al. Pazopanib in patients with primary multi-metastatic bone Ewing sarcoma. Frontiers in Oncology. 2025;15. doi:10.3389/fonc.2025.1653015
BibTeX
@article{Raciborska2025,
author = {Raciborska, Anna and Bilska, Katarzyna and Węcławek-Tompol, Jadwiga and Sega-Pondel, Dorota and Zelwiańska, Anna and Przybyszewski, Borys and Chaber, Radosław and Tomaszewska, Renata and Antoniuk-Majchrzak, Justyna and Koziński, Tomasz},
title = {Pazopanib in patients with primary multi-metastatic bone Ewing sarcoma},
journal = {Frontiers in Oncology},
year = {2025},
volume = {15},
doi = {10.3389/fonc.2025.1653015}
}
EUVIMED